search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
News


Nuffield adopts latest innovation to advance patient outcomes


Nuffield Health The Manor Hospital, in Oxford, has treated its first patients with the da Vinci Xi surgical system, a leading robotic-assisted surgical system that enables surgeons to perform surgery with greater precision. Evidence shows that patients undergoing


robotic-assisted surgery with a da Vinci surgical system experience a shorter length of stay in hospital, reduced post-operative complications and mortality, and fewer blood transfusions when compared to open or laparoscopic surgery. The da Vinci Xi surgical system works by allowing


the surgeon to view a patient’s anatomy using a highly magnified, 3D high-definition view of the surgical area. This provides the surgeon with a crystal-clear view when operating on delicate tissues and organs. At a time when demand for complex surgery continues to grow, the introduction of the da Vinci Xi surgical system will expand access to robotic-assisted surgery for patients requiring prostate, kidney and colorectal procedures, with gynaecology expected to follow later in the year. Mr Tom Leslie, Consultant Urological Surgeon at Nuffield Health The Manor Hospital, said: “The da Vinci Xi Surgical System allows us to perform complex prostate and kidney procedures with exceptional precision through a minimally invasive approach. For patients, this can mean less pain, a shorter hospital stay and a faster return to normal activities.” Miss Kat Baker, Consultant Colorectal Surgeon at Nuffield Health The Manor Hospital, added: “Robotic-assisted surgery is transforming the way we treat colorectal conditions. The enhanced vision and control provided by the da Vinci Xi system help us perform complex procedures with greater precision while supporting excellent patient outcomes.” As part of Nuffield Health’s investment in new


innovation, another hospital – Nuffield Health Parkside – has also become one of the first hospitals in the UK to introduce the pioneering Histolog Scanner for use during robotic prostatectomies, marking a significant milestone in prostate cancer treatment. Histolog is the first medical imaging device using ‘massively parallel confocal microscopy’, a cutting-edge system that enables consultants to examine prostate tissue immediately after it has been removed and assess surgical margins for any remaining cancer cells. This new approach gives surgeons a real-time assessment while the patient is still in surgery, allowing them to identify areas of concern and, where necessary, remove additional tissue immediately. It has the potential


NHS invites 500,000 men to join major prostate cancer research programme


to improve cancer control, while giving surgeons the confidence to choose techniques which help to preserve the delicate nerves and structures surrounding the prostate – limiting the risk of known complications such as incontinence and erectile disfunction. Having been introduced at two NHS hospitals in 2025, Nuffield Health is the first independent provider to adopt the system. With more than 64,000 men diagnosed with prostate cancer every year in the UK, Nuffield Health’s adoption of Histolog technology reflects its commitment to bringing innovative treatments to patients and improving outcomes. The first three Histolog-assisted procedures were completed by Mr Wissam Abou Chedid and the team at Nuffield Health Parkside Hospital in collaboration with Prostate Care Ltd. The procedures were supported by consultant histopathologist Dr. Ben Haagsma, and Dr Poonam Pingle, whose expertise helped facilitate real-time assessment of the prostate specimens during surgery.


Mr Wissam Abou-Chedid, Consultant Urological


Surgeon at Nuffield Health Parkside Hospital, said: “This is a major milestone for robotic prostate cancer surgery. This technology allows us to rapidly assess the prostate specimen and surgical margins during the operation, providing valuable real-time information that can guide our surgical decisions. “By combining advanced intraoperative margin assessment with a precise, nerve-preserving robotic approach, our aim is to maximise cancer control while minimising the risk of complications such as incontinence and erectile dysfunction. Ultimately, it is about giving our patients the best possible chance of excellent oncological and functional outcomes.” Elizabeth Dowling, Hospital Director at Nuffield


Health Parkside Hospital, said: “Investing in leading- edge technology reflects our commitment to delivering the highest standards of care. Ultimately, this is about achieving the best cancer outcomes, while preserving long-term quality of life, helping more men recover with confidence following treatment.”


10 www.clinicalservicesjournal.com I September 2026


The NHS will be contacting half a million men, inviting them to join a major research programme to improve early detection and treatment of prostate cancer. Men who have had or are living with prostate cancer will receive letters and text messages explaining how they can register to take part in what is hoped will become one of the world’s largest prostate cancer research resources. Prostate Progress, which is led by the charity


Prostate Cancer Research and supported by the NHS’s DigiTrials recruitment service, is designed to speed up the development of better tests, treatments and care. The initiative aims to recruit as many participants as possible, to improve how prostate cancer is diagnosed and treated, as well as understanding the side effects of treatment and the impact on men’s quality of life, helping to shape how future clinical trials and research are carried out. Actors Stephen Fry and Colin McFarlane


have both previously been diagnosed with prostate cancer and are both backing the NHS-supported scheme. Sir Stephen Fry, who was diagnosed with prostate cancer in 2018, has described the initiative as “genuinely hopeful” with the potential for “enormous collective good”. The programme is particularly keen to hear from Black men, who are at approximately twice the risk of developing prostate cancer, with around one in four Black men in the UK expected to be diagnosed during their lifetime. Better representation will help researchers understand and address differences in diagnosis, treatment and outcomes. Colin McFarlane, who appeared in the


Batman Begins and The Dark Knight films, is encouraging Black men to sign up, saying it will help “ourselves, our fathers, our sons, our brothers, our families and future generations”. Men who join Prostate Progress will be


asked to complete questionnaires about their experiences of living with the disease as well as agreeing for their NHS records to be securely linked and used for approved research purposes. Researchers will then compare men’s experiences of living with prostate cancer against their NHS records, including their symptoms and quality of life. The aim is to gain a better understanding of the disease, develop new treatments and tests, monitor the safety of treatments, and plan new NHS services.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85